RU2283117C1 - Antianemic and growth stimulating preparation for animals - Google Patents

Abstract

FIELD: veterinary.

SUBSTANCE: claimed preparation contains (mass %): disodium or dipotassium salt of ethylenediamine-N,N'-disuccinic acid 15.0-35.0; iron (III) 0.6-4.0; manganese (II) 0.5-2.5; copper (II) 0.05-0.25; zinc (II) 0.3-2.5; cobalt (II) 0.005-0.05; selenium (IV) 0.01-0.03; iodine (I) 0.03-0.08; vitamins: A 0.006-1.2; D3 0.00006-0.0015; E 0.1-3.5; B1 0.005-0.2; B2 0.01-0.25; B3 0.02-0.03; B4 5.5-20.0; B5 0.04-1.4; B6 0.005-1.2; and balance: water.

EFFECT: improved antianemic and growth stimulating preparation for veterinary.

6 cl, 6 tbl

Description

The invention relates to animal husbandry and veterinary medicine and can be used for the prevention and treatment of iron deficiency anemia, metabolic disorders associated with a lack of trace elements, enhance animal growth, treatment of a number of specific diseases.

Known trace element preparation hemovit-C based on a complex of a number of trace elements and iron with ethylenediamine-N, N'-disuccinic acid. The complex additionally contains selenium in the following ratio of components, wt.%: Disodium or dipotassium salt of ethylenediamine-N, N'-disuccinic acid 15-25: iron (III) 3.0-5.0; manganese (II) 0.5-2.5; copper (II) 0.25-0.50; cobalt (II) 0.1-0.3; zinc (II) 0.1-1.5; selenium (IV) 0.03-0.06; the rest of the water (RU 2130306, A 61 K 31/295, 05.20.99. Bull. No. 14).

However, the drug does not contain a complete set of vital important trace elements necessary for normal metabolism in animals. The drug is not effective enough when used in regions deficient in iodine.

Also known is an anemic and growth-promoting drug for animals - hemovit-plus (RU 2203657 05/10/2003, Bull. No. 13, A 61 K 31/295). The preparation includes a complex of iron, manganese, cobalt, copper, zinc, selenium and iodine with disodium or dipotassium salt of ethylenediamine-N, N'-di-succinic acid in the following ratio, wt.%: Disodium or potassium salt of ethylenediamine - N, N'- disuccinic acid - 15-25; iron (III) 0.6-5.0; manganese (II) 0.5-2.0; copper (II) 0.05-0.25; zinc (II) 0.1-1.5; cobalt (II) 0.005-0.05; selenium (IV) 0.01-0.03; iodine (I) 0.01-0.05; water is the rest.

The drug eliminates the deficiency of microelements, stimulates erythropoiesis, increases the nonspecific resistance of the body, and prevents white muscle disease, endemic goiter. The use of the drug enhances reproductive ability, stimulates the growth, development and productivity of farm and domestic animals.

However, the drug when using it requires the use of vitamin supplements necessary for the normal development of animals, especially in cases associated with unbalanced feeding, intoxication, anemia, the effects of acute and chronic diseases, despite the almost complete set of trace elements necessary for the body, the drug is not effective enough in cases of hypo - and vitamin deficiencies.

The objective of the invention is to increase the effectiveness of the drug containing trace elements with optimal ratios and vitamins for the prevention and treatment of metabolic disorders in farm and domestic animals, as well as poultry.

To solve this problem, a preparation based on a complex of iron, manganese, copper, zinc, cobalt, selenium and iodine with disodium or dipotassium salt of ethylenediamine-N, N'-disuccinic acid additionally contains a complex of vitamins in the following ratio of components, wt.%: Disodium or the dipotassium salt of ethylenediamine-N, N'-di-succinic acid - 15.0-35.0; iron (III) 0.6-4.0; manganese (II) 0.5-2.5; copper (II) 0.05-0.25; zinc (II) 0.3-2.5; cobalt (II) 0.005-0.05; selenium (IV) 0.01-0.03; iodine (I) 0.03-0.08; vitamins: A 0.006-1.2; D ₃ 0.00006-0.0015; E 0.1-3.5; B ₁ 0.005-0.2; B ₂ 0.01-0.25; B ₃ 0.02-0.3; B ₄ 5.5-20.0; B ₅ 0.04-1.4; B ₆ 0.005-0.12; water is the rest.

Inorganic salts, such as sulfates or chlorides in the form of hydrates or anhydrous salts, are used as a source of iron (III) and trace elements. As a source of selenium (IV), sodium selenic acid or selenic acid is used, and iodine (I) is potassium or sodium iodide. Vitamins are used as water-soluble compounds in an aqueous solution or as fat-soluble compounds when used in a dry premix. The activity of vitamin A is given based on pure alcohol-retinol, the activity of vitamin D ₃ - in terms of ergocalciferol.

According to the invention, the preparation is prepared by reacting an alkaline solution of disodium or dipotassium salt of ethylene diamine-N, N'-di-succinic acid at a pH of 11-13 and a temperature of 60-70 ° C with a calculated amount of salts of iron (III), manganese (II), copper (II) , cobalt (II), zinc (II), selenium (IV), iodine (I). After completion of the reaction, the solution is cooled to room temperature and the required amount (depending on the type of animal) of water-soluble vitamins is added. The resulting preparation is a dark brown liquid (pH 6.0-8.0). The resulting compound is well soluble in water and not soluble in organic solvents. The solution is stored in a glass or plastic container at ordinary temperature. When used in the form of a dry vitamin-mineral premix, bran, starch, lime or dolomite flour, chalk are used as filler. The composition obtained in the form of a dry premix is hygroscopic and is a light cream powder.

It is possible to use fat-soluble forms of vitamins A, E, D ₃ in a dry vitamin-mineral premix.

The use of a complex of vitamins in combination with a chelated form of trace elements can significantly increase the effectiveness of the drug by increasing the bioavailability of trace elements and a synergistic effect due to the introduction of vitamins. At the same time, metal ions do not destroy vitamins, providing the animal with the necessary minerals and vitamins.

The effectiveness of the drug can be illustrated by the following examples.

Example 1. 2 groups of puppies of 6 months of age of the German Shepherd breed were formed with 7 animals each. The groups were fed with the same diet, compiled according to Grünbaum, containing all the necessary nutritional components. The control group additionally received a hemovit-plus preparation (prototype), and the experimental group received the proposed composition containing trace elements and vitamins, wt.%: Disodium salt of ethylenediamine-N, N'-disuccinic acid - 15.0; iron (III) - 1.5; Manganese (II) - 0.9; copper (II) - 0.16; zinc (II) - 0.34; cobalt (II) - 0.04; selenium (IV) - 0.015; iodine (I) - 0.04; vitamins: A - 0.06; D ₃ - 0,00025; E - 2.0; B ₁ - 0.045; B ₂ - 0.02; B ₃ - 0.02; In ₄ - 10.0; B ₅ - 0.08; B ₆ - 0.05.

The content of vitamins was selected in accordance with the weight of the animals and their physiological state. Dosages of both drugs were similar, in accordance with the instructions for use. Clinical, biochemical and immunological studies of animal blood were carried out. The data on the beginning and end of the experiment (30 days) are given in table 1.

As follows from the data in Table 1, the experimental group showed a significant improvement in clinical indicators relative to the control, since the content of hemoglobin and leukocytes in the experimental group exceeded the control indicators by 15.4% and 25.7%, respectively. Immunological indicators also improved significantly.

Example 2. The study of the effectiveness of the drug was carried out on cows of black-motley breed 30 days before calving. The number of groups is 2, the number of animals in each group is 10.

The experimental group received the proposed drug daily, the control group received the hemovit plus drug (prototype) in similar dosages for microelements. The proposed drug had the following composition, wt.%: Disodium salt of ethylenediamine-N, N'-di-succinic acid - 20.0; iron (III) - 1.7; Manganese (II) - 1.2; copper (II) - 0.15; zinc (II) - 1.5; cobalt (II) - 0.015; selenium (IV) - 0.015; iodine (I) - 0.05; vitamins: A - 0.08; D ₃ - 0.001; E is 3.0.

Data on the clinical indicators of blood of cows at the beginning and end of the experiment (30 days) are given in table.2. The data indicate an increase in erythropoiesis and normalization of metabolism in the experimental group.

Table 1

Clinical and biochemical parameters of blood of dogs Group White blood cells, thousand / μl Red blood cells, mln / μl Hemoglobin, g / l Total protein, g / l Number of phagocytized microbial bodies in 1 μl Start end Start end Start end Start end Start the end Experience 7.04 ± 0.06 10.8 ± 0.14 4.35 ± 0.11 6.06 ± 0.09 91.8 ± 1.46 160.1 ± 2.41 59.1 ± 1.1 74.7 ± 0.97 20.48 ± 1.52 154.14 ± 5.91 Control 7.02 ± 0.06 8.9 ± 0.10 4.37 ± 0.10 7.11 ± 0.12 92.3 ± 1.33 138.7 ± 1.37 58.6 ± 1.06 65.2 ± 0.07 20.51 ± 1.24 120.53 ± 4.45

table 2
Clinical blood counts of cows Group Total protein, g / l Hemoglobin, g / l Start end Start the end Experience 75.0 ± 7.0 85.0 ± 8.5 87.5 ± 9.3 104.0 ± 11.0 Control 75.2 ± 7.0 75.1 ± 9.1 87.3 ± 9.2 93.0 ± 8.3

Data on the dynamics of labor of cows are given in table 3.

Table 3
The dynamics of labor of cows, n = 10 (30 days before calving) Group Number of obstetric aid Light calving The time of separation of the placenta To 10 10-20 more than 20 Experience - 10 9 one - Control 3 7 6 four -

A decrease in the number of obstetric aid and the time of separation of the placenta in the experimental group was noted, which indicates an improvement in the physiological status of animals.

Example 3. We studied the effectiveness of the proposed drug on calves (5-10 days) of black-motley breed. The number of animals in the experimental and control group is 10. The composition of the preparations is as in the previous example. The control group received hemovit-plus, the experimental group received the proposed vitamin-mineral preparation. Clinical indicators of animal blood before and after the experiment (30 days) are given in table 4.

Table 4
Clinical blood counts of calves (n = 10, 30 days) Group Wed live weight, kg Wed daily gain, g Hemoglobin, g / l Total protein, g / l Red blood cells, × 10 ¹² / l Start end Start end Start end Start end Experience 35.0 49.6 485 ± 25 84 ± 1.2 131 ± 9.1 52.6 ± 4.2 60.8 ± 2.7 4.9 ± 0.3 4.3 ± 0.9 Control 35.1 44.8 325 ± 40 83 ± 7.2 93 ± 9.3 52.5 ± 4.6 53.9 ± 4.1 4.8 ± 0.3 5.9 ± 0.9

The animals of the experimental group were ahead of the control in growth dynamics, the hemoglobin content increased by 40.8%, erythrocytes decreased by 37.2%, which indicates greater stimulation of erythropoiesis in the experimental group of animals.

Example 4. Studies were also carried out on sows "breed SM-1 at the age of 2.5-4 years. The experimental and control groups received the same diet and additionally the experimental group - the proposed drug, the control - the hematite-plus drug in similar dosages for trace elements. clinical studies of animal blood before and after the experiment (30 days) (Table 5) and physiological and reproductive functions of sows (Table 6). The proposed preparation had the following composition, wt.%: dipotassium salt of ethylenediamine-N, N'-di-succinic acid - 30.0; iron - 1.9; mar Anetsi - 1.2, copper - 0.15, zinc - 1.7; cobalt - 0.02; selenium - 0,020; iodine - 0.05 Vitamins,% by weight: A - 0,01; D ₃ - 0. , 0001; E - 2.0.

Table 5
Clinical indicators of pig blood (30 days) n = 10 Group Red blood cells, mln / μl Hemoglobin, g / l Total protein, g / l White blood cells, thousand / μl Start end Start end Start end Start end Experience 6.0 ± 0.4 7.1 ± 0.8 90.1 ± 3.2 118 ± 5,4 68 ± 2,3 81 ± 1,1 9.2 ± 0.08 14.7 ± 0.13 Control 6.1 ± 0.41 7.5 ± 0.75 89.7 ± 2.8 107 ± 3.3 70 ± 2.1 77 ± 1,5 9.5 ± 0.09 11.3 ± 0.1

From the data of table 5 it follows that in animals marked improvement in clinical blood counts. In the experimental group, the content of hemoglobin, total protein, and white blood cells increased with respect to the control. At the same time, the physiological status of animals increased, which positively affected the results of farrowing (Table 6). At the same time, the animals of the experimental group increased fertility, milk production and weight of the nest.

Table 6
Physiological and reproductive functions of sows Group Multiplicity, goal. Large-fruited, goal. Milk sows, kg The mass of the nest at birth, kg Experience 11.2 ± 0.3 1.18 ± 0.22 56.47 ± 1.7 13.21 ± 1.2 Control 10.44 ± 0.3 1.1 ± 0.34 50.0 ± 1.15 11.48 ± 1.39

The results obtained allow us to recommend the drug as an antanemic, normalizing metabolism and growth-promoting drug.

Thus, due to the high degree of digestibility of trace elements in a chelated state, the use of the drug significantly increases the productivity of animals and birds. The vitamins contained in the preparation are required for optimal functioning of the animal organism and act as catalysts for metabolism, increase protective functions, and restore the body's immune system.

Claims (3)

1. Antianemic and growth-promoting drug for animals, including a complex of iron, manganese, copper, zinc, cobalt, selenium and iodine with disodium or dipotassium salt of ethylenediamine-N, N'-di-succinic acid, characterized in that it additionally contains a complex of vitamins in the following the ratio of components, wt.%: disodium or dipotassium salt of ethylenediamine-N, N'-disuccinic acid 15.0-35.0; iron (III) 0.6-4.0; manganese (II) 0.5-2.5; copper (II) 0.05-0.25; zinc (II) 0.3-2.5; cobalt (II) 0.005-0.05; selenium (IV) 0.01-0.03; iodine (I) 0.03-0.08; vitamins: A 0.006-1.2; D ₃ 0.00006-0.0015; E 0.1-3.5; B ₁ 0.005-0.2; B ₂ 0.01-0.25; B ₃ 0.02-0.3; B ₄ 5.5-20.0; In ₅ 0.04-1.4; B ₆ 0.005-0.12; water the rest. 2. The drug according to claim 1, characterized in that their inorganic salts, such as sulfates or chlorides, are used as a source of iron (III) and trace elements. 3. The drug according to claim 1, characterized in that as the source of selenium (IV) use sodium selenate or selenic acid, and as a source of iodine - potassium or sodium iodide.